Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04203017 (ClinicalTrials.gov)	June 1, 2019	30/10/2019	Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis	Allogeneic Fecal Microbiota Transplantation as a Consolidation Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Sclerosis	Multiple Sclerosis	Biological: allogeneic fecal microbiota	St. Petersburg State Pavlov Medical University	NULL	Recruiting	18 Years	55 Years	All	20	Phase 1	Russian Federation
2	NCT03594487 (ClinicalTrials.gov)	November 16, 2018	7/6/2018	Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis	Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis: A Phase 1b Clinical Trial to Evaluate Feasibility, Safety, Tolerability and Effects on Immune Function	Relapsing Remitting Multiple Sclerosis	Drug: FMP30 Donor Stool;Procedure: Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool;Other: Observational Control	Jeffrey Gelfand	NULL	Active, not recruiting	18 Years	60 Years	All	30	Phase 1	United States
3	NCT03183869 (ClinicalTrials.gov)	August 24, 2017	9/5/2017	Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients	Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients	Autoimmune Diseases;Relapsing Multiple Sclerosis	Drug: Fecal microbiota	Lawson Health Research Institute	NULL	Terminated	18 Years	N/A	All	14	Phase 2	Canada